



FY 2021 (Ending March 31, 2022)  
Second Quarter Financial Results

# Reference Data

November 1, 2021

Eisai Co., Ltd.

For Inquiries:

Public Relations: TEL +81-(0)3-3817-5120

Investor Relations: TEL +81-(0)70-8688-9685

<https://www.eisai.com/>

## Forward-Looking Statements and Risk Factors

The materials and information provided in this announcement include current forecasts, targets, evaluations, estimates, assumptions that are accompanied by risks, and other matters that are based on uncertain factors. Accordingly, it is possible that actual results will deviate significantly from forecasts, etc., due to changes to a variety of factors. These risks and uncertainties include general industry and market conditions, fluctuation of interest rates and currency exchange rates, and other aspects of economic conditions in Japan and internationally.

Risks and uncertainties that could cause significant fluctuations in the results of the Group or have a material effect on investment decisions are as follows. However, these do not cover all of the risks and uncertainties faced by the Group, and it is possible that they will be affected in the future by other factors that cannot be foreseen, or are not deemed to be important, at this point in time.

These are judgments as of the time of the announcement, and statements in the text regarding the future are not guarantees that they will occur or be achieved.

Risks factors include risks related to management based on the Corporate Philosophy, risks related to establishment of AD franchise, risks related to maximization of the value of Lenvima, risks related to partnership model, risks related to digital transformation, risks related to uncertainties in new drug development, risks related to occurrences of side effects, risks related to product quality and stable supply, risks related to intellectual property, risks related to litigations, risks related to data reliability, risks related to medical cost containment measures, risks related to succession, risks related to information security, risks related to COVID-19, risks related to climate change, risks related to impairment of goodwill and intangible assets.

This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

# Contents

<b>1. Consolidated Statement of Income</b>	-----	<b>1</b>
<b>2. Segment Information</b>	-----	<b>2</b>
<b>3. Financial Results by Reporting Segment</b>	-----	<b>3</b>
<b>4. Revenue from Major Products</b>	-----	<b>7</b>
<b>5. Revenue Forecasts by Reporting Segment</b>	-----	<b>9</b>
<b>6. Consolidated Statement of Comprehensive Income</b>	-----	<b>10</b>
<b>7. Consolidated Statement of Cash Flows</b>	-----	<b>11</b>
<b>8. Capital Expenditures, Depreciation and Amortization</b>	-----	<b>12</b>
<b>9. Consolidated Statement of Financial Position</b>	-----	<b>12</b>
<b>10. Changes in Quarterly Results</b>	-----	<b>14</b>
<b>11. Stock Information</b>	-----	<b>17</b>
<b>12. Number of Employees</b>	-----	<b>18</b>
<b>13. Major R&amp;D Pipeline</b>	-----	<b>19</b>

## Currency Exchange Rates

		US (USD/JPY)	EU (EUR/JPY)	UK (GBP/JPY)	China (RMB/JPY)
FY 2020 Q2	Quarterly Average Rate	106.91	121.29	135.37	15.26
	Quarter End Rate	105.80	124.17	136.09	15.54
FY 2020	Yearly Average Rate	106.06	123.70	138.68	15.67
	Year End Rate	110.71	129.80	152.23	16.84
FY 2021 Q2	Quarterly Average Rate	109.80	130.89	152.50	16.99
	Quarter End Rate	111.92	129.86	150.43	17.30
FY 2021	Q3-Q4 Forecast Rate	<u>110.00</u>	<u>130.00</u>	<u>151.50</u>	<u>17.10</u>

\* The full year financial forecasts for FY 2021 (April 1, 2021 – March 31, 2022) have been revised from the forecasts previously announced. Revisions are underlined.

\* Eisai Co., Ltd. ("the Company") discloses its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS).

\* The Eisai Group's ("the Group") business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following six reporting segments in this report: Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia, and Oceania), Asia and Latin America (primarily South Korea, Taiwan, Hong Kong, India, ASEAN, Central and South America), and OTC and others (Japan).

\* All amounts are rounded to the nearest specified unit.

# 1. Consolidated Statement of Income

(billions of yen)

	FY 2020				FY 2021				FY 2021	
	Q2	Ratio (%)	Full year	Ratio (%)	Q2	Ratio (%)	YOY (%)	Diff.	Full year forecasts Revised	Previous
Revenue	317.0	100.0	645.9	100.0	362.4	100.0	114.3	45.3	730.0	701.0
Cost of sales	79.7	25.1	161.3	25.0	79.9	22.0	100.2	0.2	163.5	158.0
Gross profit	237.3	74.9	484.6	75.0	282.5	78.0	119.0	45.1	566.5	543.0
Selling, general and administrative expenses	133.9	42.2	281.4	43.6	154.5	42.6	115.4	20.6	325.5	321.5
Selling expenses	56.6	17.8	116.6	18.1	72.7	20.1	128.6	16.2	—	—
Personnel expenses	44.6	14.1	90.6	14.0	45.6	12.6	102.3	1.0	—	—
Administrative and other expenses	32.8	10.3	74.2	11.5	36.1	10.0	110.3	3.4	—	—
Research and development expenses	67.5	21.3	150.3	23.3	79.9	22.1	118.4	12.4	174.5	159.0
Other income	0.6	0.2	1.5	0.2	13.7	3.8	2384.4	13.1	11.5	13.5
Other expenses	2.4	0.8	2.6	0.4	0.8	0.2	34.6	(1.6)	—	—
Operating profit	34.1	10.7	51.8	8.0	60.9	16.8	178.7	26.8	78.0	76.0
Financial income	1.0	0.3	2.1	0.3	1.2	0.3	124.3	0.2	—	—
Financial costs	0.6	0.2	1.4	0.2	0.8	0.2	124.0	0.2	—	—
Profit before income taxes	34.4	10.9	52.6	8.1	61.3	16.9	178.2	26.9	78.5	76.5
Income taxes	8.3	2.6	10.1	1.6	14.8	4.1	178.2	6.5	—	—
Profit for the period	26.1	8.2	42.5	6.6	46.5	12.8	178.2	20.4	61.0	59.0
Profit for the period attributable to										
Owners of the parent	25.8	8.1	42.1	6.5	46.2	12.7	179.0	20.4	60.5	58.5
Non-controlling interests	0.3	0.1	0.4	0.1	0.4	0.1	109.1	0.0	—	—
Comprehensive income for the period	23.1	7.3	71.0	11.0	50.4	13.9	217.6	27.2		
Earnings per share (EPS, yen)	90.01		146.95		161.11				211.00	208.00
Dividend per share (DPS, yen)	80.0		160.0		80.0				160.0	160.0
Return on equity (ROE, %)	—		6.1		—				8.4	8.2
Dividends on equity ratio (DOE, %)	—		6.6		—				6.3	6.3

\* Full year forecasts for other income has had other expenses deducted from it.

\* EPS: Earnings Per Share attributable to owners of the parent (basic).

## Notes

Revenue	Continuous growth of the anticancer agent Lenvima: 91.8 billion yen (the same period in previous fiscal year: 68.5 billion yen) Receipt of an upfront payment from Bristol Myers Squibb under strategic collaboration for antibody drug conjugate MORAb-202: 49.6 billion yen
Selling, general and administrative expenses	Recording of expenses regarding shared profit of Lenvima paid to Merck & Co., Inc., Kenilworth, N.J., U.S.A.: 41.4 billion yen (the same period in previous fiscal year: 30.1 billion yen) Recording of expenses regarding launch of Alzheimer's disease treatment ADUHELM (aducanumab): 14.4 billion yen (the same period in previous fiscal year: 7.8 billion yen)
Research and development expenses	Increase due to aggressive resource investment in projects including anti amyloid-beta protofibril antibody lecanemab, ADUHELM and Lenvima Control of the expenses through the partnership model (partner's burden: 35.2 billion yen (the same period in previous fiscal year: 29.8 billion yen)) including recording of 8.3 billion yen as a regulatory milestone payment from Merck & Co., Inc., Kenilworth, N.J., U.S.A. due to approval of Lenvima for use in the treatment of renal cell carcinoma in the U.S.
Other income	Recording of profit from divestiture of rights for antiepileptic agent ZONEGRAN in Europe, the Middle East, Russia and Australia
Exchange rate effects	Revenue: +13.65 billion yen, operating profit: +5.64 billion yen
Exchange rate sensitivity (annual effect of 1 yen appreciation in currency value)	Revenue (U.S. dollars: -2.37 billion yen, Euro: -0.29 billion yen, U.K. pounds: -0.06 billion yen, Chinese renminbi: -6.93 billion yen) Operating profit (U.S. dollars: +0.49 billion yen, Euro: -0.39 billion yen, U.K. pounds: +0.08 billion yen, Chinese renminbi: -4.77 billion yen)

## 2. Segment Information

### 1) Revenue by Reporting Segment

(billions of yen)

	FY 2020		FY 2021		
	Q2	Full year	Q2	YOY (%)	CER YOY (%)
Pharmaceutical Business Total	296.1	586.1	308.4	104.2	100.2
Japan pharmaceutical business	119.6	231.9	104.0	86.9	86.9
Americas pharmaceutical business	67.5	142.8	79.8	118.3	115.0
United States	66.6	140.9	78.6	118.0	114.9
China pharmaceutical business	46.0	85.1	58.9	128.0	114.9
EMEA pharmaceutical business	26.9	55.2	28.0	104.1	96.4
Asia and Latin America pharmaceutical business	22.8	45.9	25.6	112.3	105.5
OTC and others	13.3	25.2	12.1	91.4	91.4
Other business	21.0	59.9	53.9	257.4	248.8
Consolidated revenue	317.0	645.9	362.4	114.3	110.0

\* Indicates revenue from external customers.

\* CER=Constant Exchange Rates

### 2) Profit by Reporting Segment

(billions of yen)

	FY 2020		FY 2021		
	Q2	Full year	Q2	YOY (%)	CER YOY (%)
Pharmaceutical Business Total	128.0	238.4	146.5	114.4	108.2
Japan pharmaceutical business	47.1	83.9	32.9	69.7	69.7
Americas pharmaceutical business	31.0	64.7	37.4	120.6	117.5
China pharmaceutical business	24.2	40.4	35.0	144.6	127.4
EMEA pharmaceutical business	13.1	25.7	27.4	209.2	194.1
Asia and Latin America pharmaceutical business	9.3	18.6	11.0	118.2	109.3
OTC and others	3.3	5.1	2.9	87.1	87.1
Other business	16.5	51.5	50.0	302.5	292.9
Research and development expenses	(67.5)	(150.3)	(79.9)	118.4	114.2
Group headquarters' management costs and other expenses <sup>#</sup>	(42.9)	(87.8)	(55.7)	129.6	127.2
Consolidated operating profit	34.1	51.8	60.9	178.7	162.2

\* CER=Constant Exchange Rates

<sup>#</sup> Includes the amount of profits and expenses shared under strategic collaborations with partners.

### 3. Financial Results by Reporting Segment

#### 1) Japan pharmaceutical business

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
Revenue	119.6	231.9	104.0	86.9
Segment profit	47.1	83.9	32.9	69.7
<b>Japan prescription medicines - revenue from major products</b>				
Fully human anti-TNF- $\alpha$ monoclonal antibody Humira	25.6	52.0	24.8	97.1
Peripheral neuropathy treatment Methycobal	6.3	12.4	5.3	84.1
Anticancer agent Lenvima	7.0	12.2	5.1	73.5
Insomnia treatment Dayvigo	0.8	2.0	4.7	582.0
Insomnia treatment Lunesta	6.9	13.9	4.4	63.4
Anticancer agent Halaven	4.3	8.5	4.1	96.1
Antirheumatic agent Careram	3.8	7.8	4.0	105.1
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	5.2	9.3	3.6	70.6
Elemental diet Elental <sup>#</sup>	3.3	6.6	3.4	101.3
Proton pump inhibitor Pariet <sup>#</sup>	4.2	7.9	3.3	78.3
Pain treatment (neuropathic pain, fibromyalgia) Lyrica	13.3	21.5	3.1	23.0
Chronic constipation treatment Goofice <sup>#</sup>	2.3	5.0	2.9	124.5
Antiepileptic agent Fycompa	2.6	5.1	2.6	100.2

\* The revenue for Pariet includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

\* Co-promotion revenue has been booked as revenue for Lyrica.

# EA Pharma product

## 2) Americas pharmaceutical business (North America)

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
Revenue	67.5	142.8	79.8	118.3 <115.0>
United States	66.6	140.9	78.6	118.0 <114.9>
Segment profit	31.0	64.7	37.4	120.6 <117.5>
<b>Americas - revenue from major products</b>				
Anticancer agent Lenvima	41.9	81.0	51.3	122.3 <119.0>
United States	41.5	80.1	50.8	122.3 <119.1>
	[Millions USD] [389]	[756]	[463]	
Antiepileptic agent Fycompa	6.2	12.2	7.0	113.7 <110.3>
United States	5.9	11.8	6.7	113.5 <110.5>
	[Millions USD] [55]	[111]	[61]	
Anticancer agent Halaven	6.3	12.6	6.9	109.1 <106.1>
United States	6.1	12.3	6.7	109.2 <106.3>
	[Millions USD] [58]	[116]	[61]	
Antiepileptic agent Banzel	10.3	18.9	4.7	45.3 <44.0>
United States	10.2	18.7	4.5	44.4 <43.3>
	[Millions USD] [95]	[176]	[41]	
Insomnia Treatment Dayvigo	0.1	1.1	1.6	1133.5 <1095.5>
United States	0.1	1.1	1.5	1034.0 <1006.8>
	[Millions USD] [1]	[10]	[13]	

\* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

### 3) China pharmaceutical business

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
Revenue	46.0	85.1	58.9	128.0 <114.9>
Segment profit	24.2	40.4	35.0	144.6 <127.4>
<b>China - revenue from major products</b>				
Anticancer agent Lenvima	9.1 [Millions RMB]	18.5 [1,178]	20.8 [1,226]	229.1 <205.8>
Peripheral neuropathy treatment Methycobal	12.0 [Millions RMB]	17.5 [1,116]	6.6 [386]	54.7 <49.2>
Liver disease / Allergic disease agents Stronger Neo-Minophagen C and Glycyron Tablets	5.4 [Millions RMB]	10.1 [643]	5.3 [312]	98.5 <88.4>
Proton pump inhibitor Pariet	3.1 [Millions RMB]	6.7 [430]	4.5 [266]	144.4 <129.7>
Alzheimer's disease treatment Aricept	3.4 [Millions RMB]	5.8 [367]	2.6 [151]	76.7 <68.9>
Anticancer agent Halaven	0.6 [Millions RMB]	1.6 [100]	1.2 [73]	193.0 <173.3>
Antiepileptic agent Fycompa	0.2 [Millions RMB]	0.5 [30]	0.5 [28]	223.8 <201.0>

\* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

### 4) EMEA pharmaceutical business (Europe, the Middle East, Africa, Russia and Oceania)

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
Revenue	26.9	55.2	28.0	104.1 <96.4>
Segment profit	13.1	25.7	27.4	209.2 <194.1>
<b>EMEA - revenue from major products</b>				
Anticancer agent Lenvima/Kispplx	7.5	15.8	10.0	133.9 <123.6>
Anticancer agent Halaven	6.1	12.4	6.5	106.4 <98.7>
Antiepileptic agent Fycompa	3.5	7.6	4.3	122.3 <113.0>
Antiepileptic agent Inovelon	1.2	2.5	1.3	111.1 <101.8>

\* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

## 5) Asia and Latin America pharmaceutical business

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
Revenue	22.8	45.9	25.6	112.3 <105.5>
Segment profit	9.3	18.6	11.0	118.2 <109.3>
<b>Asia and Latin America - revenue from major products</b>				
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	5.3	10.9	6.0	111.8 <104.1>
Anticancer agent Lenvima	3.1	6.5	4.6	149.6 <140.1>
Fully human anti-TNF- $\alpha$ monoclonal antibody Humira	4.1	8.5	3.8	92.8 <85.6>
Proton pump inhibitor Pariet	2.2	4.0	2.2	98.1 <92.9>
Peripheral neuropathy treatment Methycobal	1.5	3.0	1.8	118.5 <113.7>
Anticancer agent Halaven	1.3	2.6	1.2	94.0 <87.9>
Antiepileptic agent Fycompa	0.6	1.3	0.8	122.4 <114.9>

\* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

\* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.

## 6) OTC and Others (Japan)

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
Revenue	13.3	25.2	12.1	91.4
Segment profit	3.3	5.1	2.9	87.1
<b>OTC and others, revenue from major products</b>				
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	6.7	13.4	7.3	108.4



## 4. Revenue from Major Products

### 1) Neurology Products

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
<b>Neurology Products Total</b>	86.9	161.4	67.4	77.5 <74.5>
<b>Fycompa (Antiepileptic agent)</b>	13.1	26.7	15.2	115.6 <110.7>
Japan	2.6	5.1	2.6	100.2
Americas	6.2	12.2	7.0	113.7 <110.3>
China	0.2	0.5	0.5	223.8 <201.0>
EMEA	3.5	7.6	4.3	122.3 <113.0>
Asia and Latin America	0.6	1.3	0.8	122.4 <114.9>
<b>Methycobal (Peripheral neuropathy treatment)</b>	20.3	34.2	14.1	69.3 <65.7>
Japan	6.3	12.4	5.3	84.1
China	12.0	17.5	6.6	54.7 <49.2>
Asia and Latin America	1.5	3.0	1.8	118.5 <113.7>
<b>Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)</b>	14.1	26.3	12.5	88.1 <83.2>
Japan	5.2	9.3	3.6	70.6
China	3.4	5.8	2.6	76.7 <68.9>
Asia and Latin America	5.3	10.9	6.0	111.8 <104.1>
<b>Dayvigo (Insomnia treatment)</b>	1.0	3.1	6.3	665.6 <659.9>
Japan	0.8	2.0	4.7	582.0
Americas	0.1	1.1	1.6	1133.5 <1095.5>
<b>Inovelon/Banzel (Antiepileptic agent)</b>	11.8	22.0	6.3	53.5 <51.4>
Americas	10.3	18.9	4.7	45.3 <44.0>
EMEA	1.2	2.5	1.3	111.1 <101.8>
<b>Lunesta (Insomnia treatment) - Japan</b>	6.9	13.9	4.4	63.4
<b>Lyrica (Pain treatment [neuropathic pain, fibromyalgia]) - Japan</b>	13.3	21.5	3.1	23.0
<b>Other</b>	6.4	13.6	5.6	87.2 <83.7>

\* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

\* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.

\* Co-promotion revenue has been booked as revenue for Lyrica.

## 2) Oncology Products

(billions of yen)

	FY 2020		FY 2021	
	Q2	Full year	Q2	YOY (%)
<b>Oncology Products Total</b>	94.1	183.3	115.2	122.4 <116.3>
<b>Lenvima/Kispalyx (Anticancer agent)</b>	68.5	133.9	91.8	134.0 <127.3>
Japan	7.0	12.2	5.1	73.5
Americas	41.9	81.0	51.3	122.3 <119.0>
China	9.1	18.5	20.8	229.1 <205.8>
EMEA	7.5	15.8	10.0	133.9 <123.6>
Asia and Latin America	3.1	6.5	4.6	149.6 <140.1>
<b>Halaven (Anticancer agent)</b>	18.6	37.6	19.9	107.1 <102.4>
Japan	4.3	8.5	4.1	96.1
Americas	6.3	12.6	6.9	109.1 <106.1>
China	0.6	1.6	1.2	193.0 <173.3>
EMEA	6.1	12.4	6.5	106.4 <98.7>
Asia and Latin America	1.3	2.6	1.2	94.0 <87.9>
<b>Other</b>	7.0	11.8	3.5	49.6 <45.7>

\* YOY percentage: figures shown in angle brackets "< >" exclude the effects of foreign exchange fluctuations.

## 5. Revenue Forecasts by Reporting Segment (FY 2021)

(billions of yen)

	FY 2020		FY 2021		
	Q2	Full year	Q2	Full year forecasts	
				Revised	Previous
<b>Japan (Prescription Medicines)</b>	119.6	231.9	104.0	207.0	207.0
Fully human anti-TNF- $\alpha$ monoclonal antibody Humira	25.6	52.0	24.8	46.0	46.0
Anticancer agent Lenvima	7.0	12.2	5.1	12.5	12.5
Peripheral neuropathy treatment Methycobal	6.3	12.4	5.3	10.5	10.5
Anticancer agent Halaven	4.3	8.5	4.1	7.5	7.5
Antirheumatic agent Careram	3.8	7.8	4.0	7.5	7.5
Chronic constipation treatment Goofice <sup>#</sup>	2.3	5.0	2.9	7.0	7.0
Antiepilepsy agent Fycompa	2.6	5.1	2.6	6.5	6.5
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	5.2	9.3	3.6	6.5	6.5
Elemental diet Elental <sup>#</sup>	3.3	6.6	3.4	6.5	6.5
Insomnia treatment Lunesta	6.9	13.9	4.4	6.0	6.0
<b>Americas</b>	67.5	142.8	79.8	<u>165.0</u>	154.5
<b>United States</b>	66.6	140.9	78.6	<u>162.0</u>	152.0
<b>China</b>	46.0	85.1	58.9	<u>102.0</u>	91.0
<b>EMEA</b>	26.9	55.2	28.0	<u>58.0</u>	55.5
<b>Asia and Latin America</b>	22.8	45.9	25.6	<u>49.0</u>	47.5
<b>OTC and others (Japan)</b>	13.3	25.2	12.1	26.0	26.0
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	6.7	13.4	7.3	13.0	13.0
<b>Other</b>	21.0	59.9	53.9	<u>123.0</u>	119.5
<b>Consolidated revenue</b>	<b>317.0</b>	<b>645.9</b>	<b>362.4</b>	<b><u>730.0</u></b>	<b>701.0</b>
<b>Global revenue from major products</b>					
Lenvima/Kisplyx	68.5	133.9	91.8	<u>181.5</u>	172.0
Japan	7.0	12.2	5.1	12.5	12.5
Americas	41.9	81.0	51.3	<u>110.0</u>	104.5
China	9.1	18.5	20.8	<u>29.0</u>	26.5
EMEA	7.5	15.8	10.0	<u>21.5</u>	20.5
Asia and Latin America	3.1	6.5	4.6	<u>8.5</u>	8.0
Halaven	18.6	37.6	19.9	<u>39.5</u>	35.0
Japan	4.3	8.5	4.1	7.5	7.5
Americas	6.3	12.6	6.9	<u>13.0</u>	9.5
China	0.6	1.6	1.2	2.5	2.5
EMEA	6.1	12.4	6.5	<u>13.5</u>	12.5
Asia and Latin America	1.3	2.6	1.2	3.0	3.0
Fycompa	13.1	26.7	15.2	<u>33.0</u>	32.0
Japan	2.6	5.1	2.6	6.5	6.5
Americas	6.2	12.2	7.0	<u>15.0</u>	14.5
China	0.2	0.5	0.5	1.0	1.0
EMEA	3.5	7.6	4.3	<u>9.0</u>	8.5
Asia and Latin America	0.6	1.3	0.8	1.5	1.5

<sup>#</sup> EA Pharma product

## 6. Consolidated Statement of Comprehensive Income

(billions of yen)

	FY 2020		FY 2021		
	Q2	Full year	Q2	YOY (%)	Diff.
Profit for the period	26.1	42.5	46.5	178.2	20.4
Other comprehensive income (loss)					
Items that will not be reclassified to profit or loss					
Financial assets measured at fair value through other comprehensive income (loss)	1.3	3.2	(0.0)	—	(1.4)
Remeasurements of defined benefit plans	—	3.2	—	—	—
Subtotal	1.3	6.4	(0.0)	—	(1.4)
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	(4.4)	22.0	3.8	—	8.2
Cash flow hedges	0.1	0.1	0.0	77.0	(0.0)
Subtotal	(4.3)	22.2	3.8	—	8.2
Total other comprehensive income (loss), net of tax	(3.0)	28.6	3.8	—	6.8
Comprehensive income (loss) for the period	23.1	71.0	50.4	217.6	27.2
Comprehensive income (loss) for the period attributable to					
Owners of the parent	22.8	70.6	50.0	219.3	27.2
Non-controlling interests	0.3	0.4	0.3	102.5	0.0

## 7. Consolidated Statement of Cash Flows

(billions of yen)

	FY 2020	FY 2021	
	Q2	Q2	Diff.
<b>Operating activities</b>			
Profit before income taxes	34.4	61.3	26.9
Depreciation and amortization	17.7	19.3	1.6
Impairment losses	0.1	0.2	0.1
(Increase) decrease in working capital	(25.1)	4.0	29.1
Interest and dividends received	1.0	1.0	(0.0)
Interest paid	(0.5)	(0.6)	(0.1)
Income taxes paid	(10.0)	(4.8)	5.2
Income taxes refund	0.8	2.6	1.8
Other	0.2	(14.7)	(14.9)
<b>Net cash from (used in) operating activities</b>	<b>18.6</b>	<b>68.4</b>	<b>49.8</b>
<b>Investing activities</b>			
Purchases of property, plant and equipment	(12.8)	(18.3)	(5.4)
Purchases of intangible assets	(3.9)	(3.7)	0.2
Proceeds from sale of property, plant and equipment and intangible assets	0.0	13.3	13.3
Purchases of financial assets	(1.0)	(1.5)	(0.6)
Proceeds from sale and redemption of financial assets	0.1	2.3	2.2
Subtotal <Capital expenditures (cash basis)>	(17.6)	(7.9)	9.6
Payments of time deposits exceeding three months	(0.0)	(0.0)	0.0
Proceeds from redemption of time deposits exceeding three months	0.1	0.0	(0.1)
Other	0.1	(0.0)	(0.1)
<b>Net cash from (used in) investing activities</b>	<b>(17.4)</b>	<b>(8.0)</b>	<b>9.5</b>
<b>Financing activities</b>			
Proceeds from long-term borrowings	34.9	—	(34.9)
Repayments of long-term borrowings	(35.0)	—	(35.0)
Repayments of lease liabilities	(5.1)	(5.2)	(0.1)
Dividends paid	(22.9)	(22.9)	(0.0)
Other	(0.1)	0.2	0.3
<b>Net cash from (used in) financing activities</b>	<b>(28.3)</b>	<b>(27.9)</b>	<b>0.3</b>
Effect of exchange rate change on cash and cash equivalents	0.8	1.7	1.0
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(26.2)</b>	<b>34.3</b>	<b>60.5</b>
Cash and cash equivalents at beginning of period	254.2	248.7	(5.5)
Cash and cash equivalents at end of period	228.0	283.0	55.0

<b>Free cash flows</b>	<b>1.1</b>	<b>60.5</b>	<b>59.4</b>
------------------------	------------	-------------	-------------

\* "Free cash flows" = "Net cash from (used in) operating activities" - "Capital expenditures (cash basis)"

### Notes

<p>■ <b>Net cash from (used in) operating activities</b> In addition to increase in profit before income taxes, reimbursement for research and development payment was received from Bristol Myers Squibb.</p> <p>■ <b>Net cash from (used in) investing activities</b> While capital expenditures due to additional investment in research facilities and manufacturing facilities occurred, proceeds from divestiture of rights for Zonegran occurred</p> <p>■ <b>Net cash from (used in) financing activities</b> Dividends have been paid</p>
---

## 8. Capital Expenditures, Depreciation and Amortization

(billions of yen)

	FY 2020		FY 2021		FY 2021
	Q2	Full year	Q2	Diff.	Full year forecasts
Capital expenditures (cash basis)	16.7	38.1	21.9	5.3	56.0
Property, plant and equipment	12.8	19.1	18.3	5.4	23.5
Intangible assets	3.9	19.0	3.7	(0.2)	32.5
Depreciation and amortization	17.7	36.3	19.3	1.6	36.5
Property, plant and equipment	9.4	19.3	10.8	1.4	20.5
Intangible assets	8.3	17.0	8.5	0.3	16.0

## 9. Consolidated Statement of Financial Position

### <Assets>

(billions of yen)

	FY 2020		FY 2021			
	March 31, 2021	Ratio (%)	September 30, 2021	Ratio (%)	% change	Diff.
Assets						
Non-current assets						
Property, plant and equipment	160.9	14.8	159.3	14.0	99.0	(1.6)
Goodwill	171.8	15.8	173.7	15.2	101.1	1.9
Intangible assets	108.6	10.0	107.8	9.5	99.2	(0.9)
Other financial assets	43.8	4.0	43.1	3.8	98.4	(0.7)
Other assets	19.6	1.8	19.3	1.7	98.6	(0.3)
Deferred tax assets	66.9	6.1	66.2	5.8	98.9	(0.8)
Total non-current assets	571.7	52.4	569.4	49.9	99.6	(2.3)
Current assets						
Inventories	85.1	7.8	90.0	7.9	105.8	4.9
Trade and other receivables	160.3	14.7	174.6	15.3	108.9	14.3
Other financial assets	0.3	0.0	0.7	0.1	270.6	0.5
Other assets	23.9	2.2	22.3	2.0	93.5	(1.6)
Cash and cash equivalents	248.7	22.8	283.0	24.8	113.8	34.3
Total current assets	518.3	47.6	570.7	50.1	110.1	52.4
Total assets	1,090.0	100.0	1,140.1	100.0	104.6	50.1

### Notes

■ Assets	
(Trade and other receivables)	Increase in trade receivables following the increase in revenue
(Cash and cash equivalents)	Increase due to receipt of an upfront payment and reimbursement for research and development payment from Bristol Myers Squibb

## <Equity and Liabilities>

(billions of yen)

	FY 2020		FY 2021			
	March 31, 2021	Ratio (%)	September 30, 2021	Ratio (%)	% change	Diff.
Equity						
Equity attributable to owners of the parent						
Share capital	45.0	4.1	45.0	3.9	100.0	—
Capital surplus	77.6	7.1	77.6	6.8	100.0	(0.0)
Treasury shares	(34.0)	(3.1)	(34.0)	(3.0)	99.8	0.1
Retained earnings	508.0	46.6	531.2	46.6	104.6	23.2
Other components of equity	106.6	9.8	110.5	9.7	103.6	3.9
Total equity attributable to owners of the parent	703.2	64.5	730.3	64.1	103.9	27.2
Non-controlling interests	24.8	2.3	25.0	2.2	101.0	0.2
Total equity	727.9	66.8	755.3	66.3	103.8	27.4
Liabilities						
Non-current liabilities						
Borrowings	49.9	4.6	49.9	4.4	100.0	0.0
Other financial liabilities	39.8	3.7	37.7	3.3	94.8	(2.1)
Provisions	1.4	0.1	1.4	0.1	104.5	0.1
Other liabilities	14.4	1.3	14.3	1.3	99.2	(0.1)
Deferred tax liabilities	0.5	0.0	0.5	0.0	103.9	0.0
Total non-current liabilities	106.1	9.7	103.9	9.1	98.0	(2.1)
Current liabilities						
Borrowings	40.0	3.7	40.0	3.5	100.0	0.0
Trade and other payables	94.5	8.7	76.3	6.7	80.7	(18.3)
Other financial liabilities	17.0	1.6	38.8	3.4	228.5	21.8
Income taxes payable	2.5	0.2	12.0	1.1	476.4	9.5
Provisions	17.9	1.6	15.7	1.4	88.0	(2.1)
Other liabilities	84.1	7.7	98.0	8.6	116.5	13.9
Total current liabilities	256.0	23.5	280.8	24.6	109.7	24.8
Total liabilities	362.1	33.2	384.8	33.7	106.3	22.7
Total equity and liabilities	1,090.0	100.0	1,140.1	100.0	104.6	50.1

### Notes

<p>■ Equity (Retained earnings)</p>	Increase due to recording of profit for the period exceeding dividends paid
<p>■ Liabilities (Trade and other payables) (Other financial liabilities - current)</p>	<p>Decrease mainly in accounts payable - others Increase mainly in deposits received (reimbursement for research and development payment from Bristol Myers Squibb)</p>

## 10. Changes in Quarterly Results

### 1) Income Statement

(billions of yen)

	FY 2020				FY 2021	
	Q1	Q2	Q3	Q4	Q1	Q2
Revenue	165.6	151.5	181.3	147.6	198.9	163.5
Cost of sales	38.3	41.4	40.4	41.1	39.2	40.6
Gross profit	127.3	110.0	140.8	106.5	159.6	122.8
Selling, general and administrative expenses	64.9	69.0	77.5	70.0	74.7	79.8
Selling expenses	28.2	28.4	31.8	28.3	32.4	40.3
Personnel expenses	22.0	22.6	24.1	21.9	22.7	22.9
Administrative and other expenses	14.7	18.0	21.5	19.9	19.7	16.5
Research and development expenses	30.5	37.0	40.6	42.1	41.8	38.1
Other income	0.7	(0.1)	0.1	0.7	13.4	0.2
Other expenses	0.4	2.0	(0.7)	1.0	1.1	(0.3)
Operating profit	32.1	2.0	23.6	(5.9)	55.4	5.5
Financial income	0.7	0.3	0.6	0.6	0.7	0.5
Financial costs	0.3	0.3	0.3	0.4	0.4	0.4
Profit before income taxes	32.4	2.0	23.9	(5.8)	55.8	5.6
Income taxes	7.7	0.6	4.2	(2.4)	13.5	1.3
Profit for the period	24.8	1.4	19.7	(3.4)	42.3	4.2
Profit for the period attributable to						
Owners of the parent	24.4	1.4	19.4	(3.0)	42.2	4.0
Non-controlling interests	0.3	(0.0)	0.4	(0.3)	0.1	0.2
Comprehensive income for the period	23.7	(0.6)	17.3	30.6	42.4	8.0
Earnings per share (EPS, yen)	85.23	4.79	67.58	(10.63)	147.07	14.04

\* EPS: Earnings Per Share attributable to owners of the parent (basic).

### 2) Cash Flows

(billions of yen)

	FY 2020				FY 2021	
	Q1	Q2	Q3	Q4	Q1	Q2
Net cash from (used in) operating activities	10.0	8.6	3.5	51.7	(14.3)	82.7
Net cash from (used in) investing activities	(12.5)	(4.9)	(13.7)	(5.8)	0.1	(8.1)
Net cash from (used in) financing activities	(25.4)	(2.9)	(25.4)	(2.3)	(22.5)	(5.4)
Cash and cash equivalents at end of period	226.3	228.0	193.8	248.7	213.1	283.0
Free cash flow	(2.6)	3.7	(10.4)	45.7	(14.1)	74.6

\* "Free cash flow" = "Net cash from (used in) operating activities" - "Capital expenditures (cash basis)"



### 3) Capital Expenditures, Depreciation and Amortization

(billions of yen)

	FY 2020				FY 2021	
	Q1	Q2	Q3	Q4	Q1	Q2
Capital expenditures (cash basis)	12.1	4.6	14.2	7.3	14.9	7.1
Property, plant and equipment	8.8	4.0	1.6	4.7	12.1	6.1
Intangible assets	3.2	0.6	12.6	2.6	2.8	0.9
Depreciation and amortization	8.7	9.0	9.2	9.5	9.5	9.8
Property, plant and equipment	4.7	4.7	4.8	5.1	5.3	5.5
Intangible assets	4.0	4.3	4.4	4.3	4.2	4.4

### 4) Financial Positions

(billions of yen)

	Jun. 30, 2020	Sept. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Jun. 30, 2021	Sept. 30, 2021
Total assets	1,040.3	1,046.6	1,028.6	1,090.0	1,129.3	1,140.1
Equity	703.3	702.8	697.2	727.9	747.4	755.3
Attributable to owners of the parent	678.6	678.2	672.2	703.2	722.6	730.3
Liabilities	337.0	343.8	331.4	362.1	382.0	384.8
Borrowings	89.9	89.9	89.9	89.9	92.7	89.9
Ratio of equity attributable to owners of the parent (%)	65.2	64.8	65.4	64.5	64.0	64.1
Net debt equity ratio (times)	(0.25)	(0.25)	(0.20)	(0.27)	(0.20)	(0.30)

\* "Net debt equity ratio (Net DER)" = ("Interest-bearing debt" ("Borrowings") - "Cash and cash equivalents" -

"Time deposits exceeding three months, etc." - "Investment securities held by the parent") / "Equity attributable to owners of the parent"

## 5) Changes in Quarterly Revenue from Major Products

### (1) Neurology Products

(billions of yen)

	FY 2020				FY 2021	
	Q1	Q2	Q3	Q4	Q1	Q2
<b>Neurology Total</b>	43.8	43.1	40.4	34.0	34.1	33.3
<b>Fycompa (Antiepileptic agent)</b>	6.4	6.7	7.0	6.7	7.4	7.7
Japan	1.2	1.4	1.3	1.3	1.2	1.4
Americas	3.0	3.1	3.2	2.9	3.4	3.5
China	0.1	0.1	0.2	0.0	0.2	0.3
EMEA	1.7	1.8	2.0	2.1	2.2	2.2
Asia and Latin America	0.3	0.3	0.3	0.4	0.4	0.4
<b>Methycobal (Peripheral neuropathy treatment)</b>	10.9	9.4	6.3	7.6	6.8	7.3
Japan	3.3	3.0	3.0	3.1	2.4	2.8
China	6.9	5.1	2.1	3.4	3.3	3.3
Asia and Latin America	0.6	0.9	0.7	0.8	0.9	0.9
<b>Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)</b>	7.8	6.3	6.2	6.0	6.3	6.1
Japan	2.9	2.3	2.2	1.9	1.8	1.9
China	2.2	1.2	1.1	1.3	1.4	1.2
Asia and Latin America	2.6	2.7	2.8	2.7	3.0	2.9
<b>Dayvigo (Insomnia treatment)</b>	0.1	0.8	0.8	1.3	2.6	3.7
Japan	0.1	0.7	0.4	0.8	1.9	2.9
Americas	0.0	0.1	0.4	0.6	0.8	0.8
<b>Inovelon/Banzel (Antiepileptic agent)</b>	5.9	5.9	5.5	4.7	3.7	2.6
Americas	5.1	5.1	4.7	4.0	2.8	1.8
EMEA	0.6	0.6	0.7	0.6	0.7	0.7
<b>Lunesta (Insomnia treatment) - Japan</b>	3.6	3.3	3.5	3.5	2.9	1.5
<b>Lyrica (Pain treatment [neuropathic pain, fibromyalgia]) - Japan</b>	6.1	7.2	7.1	1.1	1.6	1.5
<b>Other</b>	3.0	3.4	4.0	3.2	2.8	2.8

\* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.

\* Co-promotion revenue has been booked as revenue for Lyrica.

### (2) Oncology Products

(billions of yen)

	FY 2020				FY 2021	
	Q1	Q2	Q3	Q4	Q1	Q2
<b>Oncology Total</b>	47.7	46.4	48.2	40.9	56.1	59.1
<b>Lenvima/Kispilix (Anticancer agent)</b>	34.7	33.8	35.3	30.2	44.2	47.6
Japan	3.7	3.3	2.8	2.4	2.5	2.6
Americas	21.5	20.4	20.2	18.8	24.4	26.9
China	4.2	4.9	6.0	3.3	10.5	10.3
EMEA	3.9	3.5	4.3	4.0	4.8	5.1
Asia and Latin America	1.4	1.7	1.9	1.5	2.0	2.6
<b>Halaven (Anticancer agent)</b>	9.4	9.2	9.5	9.5	10.2	9.8
Japan	2.2	2.1	2.0	2.2	2.0	2.1
Americas	3.2	3.1	3.2	3.1	3.3	3.6
China	0.1	0.5	0.6	0.4	0.9	0.3
EMEA	3.2	2.9	3.1	3.2	3.4	3.0
Asia and Latin America	0.7	0.6	0.7	0.6	0.6	0.6
<b>Other</b>	3.6	3.4	3.4	1.3	1.7	1.8

# 11. Stock Information

## 1) Number of Shares Issued and Shareholders

As of September 30, 2021

Total Number of Authorized Shares	Number of Shares Issued and Outstanding	Number of Shares Held as Treasury Stock	Number of Shareholders	Average Number of Shares per Shareholder
1,100,000,000	296,566,949	9,815,591	61,220	4,844

\* Number of shares issued and outstanding includes treasury stock.

## 2) Principal Shareholders

As of September 30, 2021

Shareholders	Shares (1,000 shares)	Percentage of shares held (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	50,313	17.55
Custody Bank of Japan, Ltd. (Trust Account)	33,393	11.65
State Street Bank and Trust Company 505001	19,321	6.74
Nippon Life Insurance Company	9,781	3.41
Saitama Resona Bank, Limited	6,300	2.20
Custody Bank of Japan, Ltd. (Trust Account 7)	6,052	2.11
State Street Bank West Client - Treaty 505234	4,217	1.47
The Naito Foundation	4,212	1.47
Government of Norway	3,801	1.33
JP Morgan Chase Bank 385781	3,428	1.20

\* Number of shares has been rounded down to the nearest thousand.

\* The percentage of shares held is calculated in proportion to the number of shares issued and outstanding (excluding treasury stock).

\* Treasury stock (9,815 thousand shares, the percentage of treasury stock calculated in proportion to the number of shares issued and outstanding: 3.31%) has been excluded from the table as it has no voting rights.

\* While the large shareholding reports (amendment reports) received up until September 30, 2021 are listed below, in cases where large shareholdings cannot be confirmed by the shareholder registry as of September 30, 2021 or where the number of shares held does not account among the top 10 shareholders, such shareholders are not listed in the above table. Furthermore, the percentage of shares held (rounded down) given inside the brackets is calculated in proportion to the number of shares issued and outstanding including treasury stock.

(1) As of July 13, 2015, four companies including Mitsubishi UFJ Financial Group jointly hold 16,113 thousand shares (5.43%).  
(Amendment report dated July 21, 2015)

(2) As of July 31, 2015, two companies including the Wellington Management Company, LLP jointly hold 27,087 thousand shares (9.13%).  
(Amendment report dated August 7, 2015)

(3) As of August 15, 2017, eleven companies including BlackRock Japan Co., Ltd. jointly hold 18,308 thousand shares (6.17%).  
(Amendment report dated August 21, 2017)

(4) As of December 14, 2018, three companies including Sumitomo Mitsui Trust Bank, Ltd. jointly hold 15,967 thousand shares (5.38%).  
(Amendment report dated December 21, 2018)

(5) As of July 15, 2020, three companies including Nomura Securities Co., Ltd. hold 18,380 thousand shares (6.20%).  
(Amendment report dated July 21, 2020)

(6) As of September 15, 2020, Bank's Shareholdings Purchase Corporation holds 14,945 thousand shares (5.04%).  
(Large shareholding report dated September 23, 2020)

## 3) Number of Shares Held by Category

(1,000 shares)

	March 31, 2021	Ratio (%)	September 30, 2021	Ratio (%)	Diff.
Financial institutions	129,991	43.8	127,013	42.8	(2,977)
Financial instruments traders (securities companies)	8,872	3.0	9,202	3.1	330
Other companies	19,381	6.5	18,415	6.2	(965)
Foreign entities, etc.	89,495	30.2	95,311	32.1	5,815
Individuals, other	38,986	13.1	36,808	12.4	(2,178)
Treasury stock	9,839	3.3	9,815	3.3	(23)
Total	296,566	100.0	296,566	100.0	—

\* Number of shares has been rounded down to the nearest thousand.

## 12. Number of Employees

### 1) Number of Employees on Consolidated Basis

(employees)

	March 31, 2019	March 31, 2020	March 31, 2021	September 30, 2021
Total employees	10,683	10,998	11,237	11,373
Japan	4,888	4,593	4,613	4,664
Americas (North America)	1,261	1,682	1,820	1,852
China	2,069	2,087	2,060	2,128
EMEA (Europe, the Middle East, Africa, Russia and Oceania)	1,046	1,113	1,166	1,194
Asia and Latin America	1,419	1,523	1,578	1,535

### 2) Number of Employees on Non-Consolidated Basis

(employees)

	March 31, 2019	March 31, 2020	March 31, 2021	September 30, 2021
Total employees (Eisai Co., Ltd.)	3,140	2,953	3,005	3,057
Production	408	367	375	389
Research and development	868	839	857	867
Sales, marketing and administration	1,864	1,747	1,773	1,801

\* The number of total employees shown above includes staff dispatched to Eisai Co., Ltd. from other group companies, and excludes the employees of Eisai Co., Ltd. dispatched to other group companies.

## 13. Major R&D Pipeline

### (1) Neurology

Development Code: <b>E2007</b> Generic Name: <b>perampanel</b> Product Name: <b>Fycompa</b>					In-house
Indications / Drug class: Antiepileptic agent / AMPA receptor antagonist					Oral
Description: A selective antagonist against the AMPA receptor (a glutamate receptor subtype). Approved as an adjunctive therapy for partial-onset seizures in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. Approved for monotherapy and adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Japan, the United States and China. Approved for adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Europe. Also approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, and other countries in Europe and in Asia. Approved for an adjunctive therapy for primary generalized tonic-clonic seizures in patients 7 years of age and older in Europe, and 12 years of age and older in Japan and United States. An oral suspension formulation has been approved in the United States and other countries in Europe. A fine granule formulation has been approved in Japan.					
	Pediatric epilepsy (Additional Dosage and Administration)	Study 311	CH	◎	Approved (July, 2021)
	Monotherapy for partial-onset seizures (Additional Indication)	Study 335	CH	◎	Approved (July, 2021)
	Lennox-Gastaut syndrome (Additional Indication)	Study 338	JP/US/EU		PIII

Development Code: <b>E2006</b> Generic Name: <b>lemborexant</b> Product Name: <b>Dayvigo</b>					In-house
Indications / Drug class: Insomnia treatment / Orexin receptor antagonist					Oral
Description: An orexin receptor antagonist that blocks the receptors involved in the regulation of sleep and wakefulness. It is expected to alleviate wakefulness, thereby facilitating onset and maintenance of sleep. It has been approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults in the United States, Canada and others. It has been approved for the treatment of insomnia in Japan and India. In addition, development for irregular sleep-wake rhythm disorder and Alzheimer's disease dementia is ongoing.					
◎	Insomnia disorder	Study 311	CH		PIII
	Irregular sleep-wake rhythm disorder and Alzheimer's disease dementia (Additional Indication)	Study 202	JP/US		PII

Development Code: <b>BIIB037</b> Generic Name: <b>aducanumab</b> Product Name: <b>ADUHELM</b>					Co-development (Biogen Inc.)
Indications / Drug class: Treatment for Alzheimer's disease / anti-A $\beta$ monoclonal antibody					Injection
Description: A human recombinant monoclonal antibody (mAb) that is derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune's technology platform, Reverse Translational Medicine (RTM). Biogen Inc. licensed aducanumab from Neurimmune. Aducanumab is thought to target aggregated forms of amyloid beta (A $\beta$ ) including soluble oligomers and insoluble fibrils, which can form into amyloid plaque in Alzheimer's disease (AD) patients. The United States Food and Drug Administration (FDA) granted accelerated approval as the first and only AD treatment to address a defining pathology of the disease in June 2021. Continued approval for ADUHELM's indication as a treatment for AD may be contingent upon verification of clinical benefit in confirmatory trial(s). New drug applications seeking approval for the treatment of AD were submitted in Japan, Europe and others. Joint development with Biogen Inc.					
	Alzheimer's disease	ENGAGE/ EMERGE Studies	US EU JP	○	Approved (June, 2021) Submitted (accepted: October, 2020) Submitted (December, 2020)

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

○ : Development progress from April 2021 onwards ◎ : Development progress from July 2021 onwards

Development Code: <b>BAN2401</b> Generic Name: <b>lecanemab</b>				In-license (BioArctic AB)
Indications / Drug class: Disease modifying treatment for Alzheimer's disease / anti-A $\beta$ protofibril antibody				Injection
Description: An IgG1 antibody that targets A $\beta$ protofibrils. Expected to be effective in the treatment of AD by halting disease progression through the elimination of neurotoxic A $\beta$ protofibrils. The Phase III clinical study Clarity AD in patients with mild cognitive impairment due to AD or mild AD (collectively known as early AD) is underway. The Phase III clinical study AHEAD 3-45 for preclinical (asymptomatic) AD has been initiated and is underway in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC). FDA granted Breakthrough Therapy designation in June 2021, and a rolling submission to the FDA for the Biological License Application for early AD has been initiated under the accelerated approval pathway in September 2021. Joint development with Biogen Inc.				
Early AD	Study 201	US	©	Rolling submission (initiated: September 2021)
	Study 301 (Clarity AD)	JP/US/ EU/CH		PIII
Preclinical AD	Study 303 (AHEAD 3-45)	JP/US /EU		PIII

Development Code: <b>E2023</b> Generic Name: <b>lorcaserin</b>				In-license (Arena Pharmaceuticals)
Indications / Drug class: Treatment for Dravet syndrome / serotonin 2C receptor agonist				Oral
Description: By selectively activating serotonin 2C receptors in the brain, through the activation GABAergic inhibitory interneuron, expected to suppress seizure of Dravet syndrome by increasing synaptic suppression from GABAergic. Although approval for the obesity indication has been voluntarily withdrawn, due to the request from Dravet syndrome patient groups, the extended access program has been continued in the United States, and the Phase III clinical study is underway for this indication. FDA has designated it as an orphan drug for Dravet syndrome.				
Dravet syndrome	Study 304	US		PII

Development Code: <b>E2027</b>				In-house
Indications / Drug class: Treatment for dementia with Lewy bodies, Parkinson's disease dementia / PDE9 inhibitor				Oral
Description: A selective phosphodiesterase (PDE) 9 inhibitor that reduces the degradation of cyclic GMP, which is critical to signal transduction among cells. Expected to be a new treatment for dementia with Lewy bodies and Parkinson's disease dementia by helping to maintain the concentration of cyclic GMP in the brain.				
Dementia with Lewy bodies, Parkinson's disease dementia	Study 203	US		PII

Development Code: <b>E2730</b>				In-house
Indications / Drug class: Antiepileptic agent, treatment for neurological diseases / synapse function modulator				Oral
Description: A compound with a novel mechanism of action that selectively regulates the function of activated synapses. Expected to be a new treatment for neurological diseases such as epilepsy, including orphan epilepsy, and epileptogenesis.				
Epilepsy	Study 201	US		PII

Development Code: <b>E2814</b>				Collaboration (University College London)
Indications / Drug class: anti-MTBR tau antibody				Injection
Description: E2814 is anti-MTBR tau antibody that was discovered as part of the research collaboration between Eisai and University College London. Expected to prevent the spreading of tau seeds within the brain. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) has selected E2814 as the first investigational medicine among anti-tau drugs for their DIAN-TU tau study. A Phase Ib/II study for dominantly inherited AD has been initiated.				
© Alzheimer's disease	Study103	US/EU		PI/II

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

○ : Development progress from April 2021 onwards © : Development progress from July 2021 onwards

Development Code: <b>E2511</b>			In-house	
Indications / Drug class: Synapse regenerant			Oral	
Description: E2511 is expected to promote recovery and synaptic remodeling of damaged cholinergic neurons, and to suppress cerebral atrophy caused by neurodegeneration.				
Alzheimer's disease	—	US		PI

Development Code: <b>EA4017</b>			In-house		Oral
Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma)	—	JP		PI	

## (2) Oncology

Development Code: <b>E7080</b> Generic Name: <b>lenvatinib</b> Product Name: <b>Lenvima</b>					In-house
Indications / Drug class: Anticancer agent / kinase inhibitor					Oral
Description: An orally administered multiple receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR) in addition to other proangiogenic and oncogenic pathway related RTKs (including the platelet-derived growth factor receptor (PDGFR), KIT and RET) involved in angiogenesis and tumor proliferation. Discovered and developed in-house. Approved for use in the treatment of thyroid cancer in over 75 countries including Japan, the United States, China and other countries in Europe and in Asia. Approved for use in the treatment of thymic carcinoma in Japan. Also approved in combination with everolimus for use in the treatment of renal cell carcinoma (second-line) in over 60 countries including the United States and other countries in Europe. The agent is marketed under the product name Kisplyx only for this indication in Europe. Approved for use in the treatment of hepatocellular carcinoma (first-line) in over 70 countries including in Japan, the United States, China and other countries in Europe and in Asia. Approved for use in the treatment of endometrial carcinoma (following prior systemic therapy) in combination with pembrolizumab in the United States in July 2021 and approved for the similar indication (including conditional approval) in over 10 countries such as Canada and Australia. Approved for use in the treatment of renal cell carcinoma (first-line) in combination with pembrolizumab in the United States in August 2021. It has received orphan drug designation with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW) in Japan. Joint development with Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate.					
In combination with anti-PD-1 antibody pembrolizumab, joint development with Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate (Additional Indication)					
	Endometrial carcinoma, following prior systemic therapy	Study 309	US EU JP	◎  ○	Approved (July, 2021) Submitted (accepted: March, 2021) Submitted (April, 2021)
	Renal cell carcinoma/First-line	Study 307	US EU JP	◎	Approved (August, 2021) Submitted (accepted: March, 2021) Submitted (March, 2021)
	Endometrial carcinoma/First-line	LEAP-001	JP/US/EU/ CH		PIII
	Hepatocellular carcinoma/First-line	LEAP-002	JP/US/EU/ CH		PIII
	Melanoma/First-line	LEAP-003	US/EU/CH		PIII
	Non-small cell lung cancer (nonsquamous) (in combination with chemotherapy)/First-line	LEAP-006	JP/US/EU/ CH		PIII
	Non-small cell lung cancer/Second-line	LEAP-008	JP/US/EU		PIII
	Head and neck cancer/First-line	LEAP-010	JP/US/EU/ CH		PIII
	Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization)/First-line	LEAP-012	JP/US/EU/ CH		PIII
◎	Esophageal carcinoma (in combination with chemotherapy) /First-line	LEAP-014	JP/US/EU/ CH		PIII
	Gastric cancer (in combination with chemotherapy)/First-line	LEAP-015	JP/US/EU/ CH		PIII
	Colorectal cancer (non MSI-H/pMMR)/Third-line	LEAP-017	US/EU		PIII
	Melanoma/Second-line	LEAP-004	US/EU		PII
	Selected solid tumors (Gastric cancer, colorectal cancer, glioblastoma, biliary tract cancers and pancreatic cancer)	LEAP-005	US/EU		PII
	Head and neck cancer/Second-line	LEAP-009	US/EU		PII
	Selected solid tumors (Endometrial carcinoma, renal cell carcinoma, head and neck cancer, bladder cancer, non-small cell lung cancer and melanoma)	Study 111 —	US/EU JP		PI/II PI
In combination with anticancer agent everolimus, joint development with Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate (Additional Indication)					
	Renal cell carcinoma/First-line	Study 307	JP/US/EU		PIII

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

○ : Development progress from April 2021 onwards ◎ : Development progress from July 2021 onwards



In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication)				
Hepatocellular carcinoma	—	JP		PI

○ Based on the external Data Monitoring Committee recommendation, Phase III clinical study of LEAP-007 for Non-small cell lung cancer, PD-L1 positive/First-line has been decided to be discontinued and therefore was removed from this list.

◎ Based on the external Data Monitoring Committee recommendation, Phase III clinical study of LEAP-011 for cisplatin-ineligible bladder cancer, First-line has been decided to be discontinued and therefore was removed from this list.

Development Code: <b>E7389</b> Generic Name: <b>eribulin</b> Product Name: <b>Halaven</b>				In-house
Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor				Injection
Description: A synthetic analog of halichondrin B derived from the marine sponge <i>Halichondria okadai</i> . Shows an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Approved in over 75 countries including Japan, the United States, China and other countries in Europe and in Asia for use in the treatment of breast cancer. Approved in over 75 countries including Japan, the United States and other countries in Europe and in Asia for use in the treatment of liposarcoma (soft tissue sarcoma in Japan).				
Monotherapy (Additional Formulation)				
Liposomal formulation	—	JP/EU		PI
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation)				
Liposomal formulation	Study 120	JP		PI/II

Development Code: <b>E7438</b> Generic Name: <b>tazemetostat</b> Product Name: <b>Tazverik</b>				In-license (Epizyme, Inc.)
Indications / Drug class: Anticancer agent / EZH2 inhibitor				Oral
Description: Believed to have an important role in carcinogenesis, the epigenetic enzyme EZH2 is one of the proteins that constitute the histone methyltransferases. Discovered by Epizyme, Inc. through its proprietary product platform, tazverik is a first-in-class, orally administered small molecule inhibitor, and is expected to exhibit antitumor effects via inhibition of the epigenetic enzyme EZH2. Eisai holds development and commercialization rights within Japan. In June 2021, approved for <i>EZH2</i> gene mutation-positive follicular lymphoma in Japan.				
Non-Hodgkin B-cell lymphoma	Study 206	JP	○	Approved (June, 2021)

Development Code: <b>H3B-6545</b>				In-house
Indications / Drug class: Anticancer agent / ERα inhibitor				Oral
Description: An orally administered selective estrogen receptor (ER) α covalent antagonist that inhibits ERα wild type / ERα mutant. Expected to show an antitumor effect against ER positive / HER2 negative breast cancers.				
Breast cancer	Study 101	US/EU		PI/II
Breast cancer (in combination with CDK4/6 inhibitor palbociclib)	—	US/EU		PI

Development Code: <b>E7090</b>				In-house
Indications / Drug class: Anticancer agent / FGFR1,2,3 inhibitor				Oral
Description: An orally administered fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor. Phase II clinical study for unresectable cholangiocarcinoma (one of biliary tract cancers) with <i>FGFR2</i> gene fusion is ongoing. It has received orphan drug designation with a prospective indication for unresectable biliary tract cancer with <i>FGFR2</i> gene fusion by the MHLW.				
Cholangiocarcinoma	Study 201	JP/CH		PII
Breast cancer	—	JP		PI

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

○ : Development progress from April 2021 onwards ◎ : Development progress from July 2021 onwards

Development Code: <b>MORAb-202</b>				In-house	
Indications / Drug class: Anticancer agent / farletuzumab- eribulin conjugate				Injection	
Description: MORAb-202 is the antibody drug conjugate (ADC) with approved anticancer drug eribulin. Expected to show an antitumor effect against folate receptor $\alpha$ -positive tumors by concentrating eribulin on tumor; inclusive of endometrial, ovarian, lung and breast cancers. In June 2021, Eisai entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization with Bristol Myers Squibb.					
	Solid tumors	—	US		PI/II
	Solid tumors	—	JP		PI

Development Code: <b>E7386</b>			Collaboration (PRISM BioLab)		Oral
◎	Solid tumors (in combination with pembrolizumab)	Study 201	JP/US		PI/II
	Solid tumors	—	JP/EU		PI
	Solid tumors (in combination with lenvatinib)	—	JP		PI

Development Code: <b>H3B-6527</b>			In-house		Oral
	Hepatocellular carcinoma	—	US/EU		PI

Development Code: <b>H3B-8800</b>			In-house		Oral
	Blood cancer	—	US/EU		PI

Development Code: <b>E7130</b>			Collaboration (Harvard University)		Injection
	Solid tumors	—	JP		PI

Development Code: <b>E7766</b>			In-house		Injection
	Solid tumors	—	US/EU		PI

○ Phase I/II study of MORAb-009 for mesothelioma in the United States and Europe has been finished and therefore was removed from this list.

### (3) Gastrointestinal Disorders

Development Code: <b>AJM300</b> Generic Name: <b>carotegrast methyl</b>				In-house
Indications / Drug class: Ulcerative colitis treatment / $\alpha$ 4 integrin antagonist				Oral
Description: $\alpha$ 4 integrin antagonist with a novel mechanism of action believed to suppress adhesion and infiltration of lymphocytes. Aiming to be marketed as the first orally-available $\alpha$ 4 integrin antagonist in the world to be effective in ulcerative colitis. In May 2021, EA Pharma filed the New Drug Application in Japan. Joint development by EA Pharma and Kissei Pharmaceutical.				
Ulcerative colitis	—	JP	○	Submitted (May, 2021)

Development Code: <b>E6007</b> Generic Name: <b>milategrast</b>				In-house
Indications / Drug class: Ulcerative colitis treatment / integrin activation inhibitor				Oral
Description: A compound with a novel mechanism of action that is believed to suppress the adhesion and infiltration of multiple leukocyte types by inhibiting integrin activation. EA Pharma aims for commercialization jointly with the University of Tsukuba as an industry-academia practical application project under the Japan Science and Technology Agency. Development conducted by EA Pharma.				
Ulcerative colitis	Study 201	JP		PII

Development Code: <b>E6011</b> Generic Name: <b>quetmolimab</b>				In-house
Indications / Drug class: Crohn's disease / humanized anti-fractalkine monoclonal antibody				Injection
Description: The world's first humanized anti-fractalkine monoclonal antibody discovered by the Eisai Group subsidiary KAN Research Institute. Expected to exert an anti-inflammatory effect by neutralizing fractalkine. Fractalkine is found in vascular endothelial cells and induces an inflammatory response associated with diseases such as inflammatory bowel disease. Development conducted by EA Pharma.				
Crohn's disease	Study ET2	JP/EU		PII

Development Code: <b>E3112</b>			In-house	Injection
Liver disease (Development conducted by EA Pharma)	—	JP		PI

Development Code: <b>AJM347</b>			In-house	Oral
Inflammatory bowel disease (Development conducted by EA Pharma)	—	EU		PI

Development Code: <b>EA1080</b>			In-house	Oral
Inflammatory bowel disease (Development conducted by EA Pharma)	—	EU		PI

Development Code: <b>EA3355</b>			In-license (Dr. Falk Pharma)	Oral
Liver disease (Development conducted by EA Pharma)	—	JP		PI

© Due to changing business priorities, EA Pharma is no longer progressing the development on Phase I/II study in Japan of EA4000 as bowel cleansing agent and therefore was removed from this list.

#### (4) Other

Development Code: <b>D2E7</b> Generic Name: <b>adalimumab</b> Product Name: <b>Humira</b>				In-license (AbbVie GK)
Indications / Drug class: Fully human anti-TNF $\alpha$ monoclonal antibody				Injection
Description: A fully human anti-TNF $\alpha$ monoclonal antibody, which neutralizes tumor necrosis factor alpha (TNF $\alpha$ ), a type of cytokine that plays a central role in inflammatory reactions in patients with autoimmune diseases. Approved in Japan for the treatment of rheumatoid arthritis (including inhibition of the progression of structural damage), psoriasis, Crohn's disease, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, intestinal Behçet's disease, ulcerative colitis, non-infectious uveitis, hidradenitis suppurativa, and pyoderma gangrenosum.				
©	Ulcerative Colitis (High-Dosage in Adult and Pediatric)	—	JP	Approved (September, 2021)

Development Code: <b>E5564</b> Generic Name: <b>eritoran</b>				In-house
Indications / Drug class: Suppression for increasing of severity of COVID-19/ TLR4 antagonist				Injection
Description: Eritoran is a TLR (Toll-Like Receptor) 4 antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A which is an activator of endotoxins of bacteria. It is expected to suppress inflammation and increasing in severity caused by COVID-19 by inhibiting the activation of TLR4, which is found in the most upstream position of various cytokine gene expression signaling that causes the cytokine-storm. Joint development with GCAR (Global Coalition for Adaptive Research).				
	Suppression for increasing of severity of COVID-19	REMAP-COVID	US	PIII

Development Code: <b>E6742</b>			In-house	Oral
	Autoimmune disease	—	JP/US	PI

Development Code: <b>E8001</b>			In-house	Injection
	Rejection reaction associated with organ transplantation	—	JP	PI

JP: Japan, US: the United States, EU: Europe, CH: China, P: (Clinical trial) Phase

○ : Development progress from April 2021 onwards © : Development progress from July 2021 onwards